Nebulized amphotericin B does not improve exacerbation-free status at 1 year for patients with bronchopulmonary aspergillosis, though it may delay onset and incidence. Investigators searched PubMed ...
In a recent retrospective observational study, 90-day mortality was similar across groups: 37.1% with initial triazole therapy versus 41.3% with initial L-AmB. These findings are reassuring, ...
These findings support the safety and use of single high-dose liposomal amphotericin B over alternative treatment options. For patients with HIV-associated fungal infections, single high-dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results